Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012
Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019
Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Occupational and environmental impact on the clinical course of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Baseline characteristics of an Italian cohort of pulmonary alveolar proteinosis (PAP) patients Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011
Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010
Baseline characteristics of the Italian cohort of patients affected by pulmonary alveolar proteinosis (PAP) Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008
Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Clinical assessment and management of pulmonary alveolar proteinosis: the importance of a reference centre Source: Annual Congress 2009 - Pulmonary alveolar proteinosis: clearing the Milky Way Year: 2009
Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Serum interleukin 18 as a monitoring marker of long clinical course of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 711s Year: 2004
Relationship between macrophage inflammatory protein-3β(MIP-3β) levels and clinical course of sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021
Clinical and paraclinical manifestations of pulmonary alveolar proteinosis in children Source: Eur Respir J 2007; 30: Suppl. 51, 402s Year: 2007
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
Cross-sectional evaluation of serum and sputum calprotectin in bronchiectasis disease monitoring Source: International Congress 2019 – Bronchiectasis Year: 2019
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016